Table 1b.
Baseline characteristics (continued). The baseline characteristics of proinflammatory cytokines and inflammation markers as well as haemodynamic parameters as measured after the 2-week placebo run-in period. The data between parentheses represent the SD
| T2DM patients | Healthy volunteers | |||
|---|---|---|---|---|
| Parameter | Male | Female | Male | Female |
| White blood cell count (109 l−1) | 5.3 (1.06) | 5.5 (1.32) | 5.6 (1.01) | 4.8 (0.58) |
| High-sensitivity C-reactive protein (mg l−1) | 1.5 (0.80) | 3.2 (2.63) | 1.1 (2.23) | 1.7 (2.34) |
| IL-1β level (pg ml−1) | 0.19 (0.184) | 0.08 (0.047) | 0.08 (0.089) | 0.08 (0.075) |
| IL-6 level (pg ml−1) | 2.5 (1.58) | 2.7 (1.15) | 1.9 (1.87) | 1.1 (0.50) |
| Tumour necrosis factor-α (pg ml−1) | 1.7 (0.65) | 3.5 (3.94) | 3.4 (2.58) | 2.3 (1.66) |
| Systolic blood pressure (mmHg) | 129 (11.4) | 126 (24.0) | 119 (9.8) | 115 (5.9) |
| Diastolic blood pressure (mmHg) | 78 (5.5) | 75 (8.5) | 69 (8.1) | 70 (8.5) |
| Heart rate (bpm) | 66 (10.7) | 72 (10.8) | 69 (12.9) | 69 (12.0) |